Switch to:
Also traded in: Austria, Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.01
SHPG's Cash-to-Debt is ranked lower than
100% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. SHPG: 0.01 )
Ranked among companies with meaningful Cash-to-Debt only.
SHPG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.18 Max: No Debt
Current: 0.01
Equity-to-Asset 0.47
SHPG's Equity-to-Asset is ranked lower than
74% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SHPG: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
SHPG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.56 Max: 0.85
Current: 0.47
0.25
0.85
Debt-to-Equity 0.69
SHPG's Debt-to-Equity is ranked lower than
78% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. SHPG: 0.69 )
Ranked among companies with meaningful Debt-to-Equity only.
SHPG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.29 Max: 1.12
Current: 0.69
0
1.12
Interest Coverage 2.02
SHPG's Interest Coverage is ranked lower than
96% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 2.02 )
Ranked among companies with meaningful Interest Coverage only.
SHPG' s Interest Coverage Range Over the Past 10 Years
Min: 2.02  Med: 27.36 Max: 55.13
Current: 2.02
2.02
55.13
Piotroski F-Score: 4
Altman Z-Score: 1.17
Beneish M-Score: -1.86
WACC vs ROIC
7.93%
2.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 8.61
SHPG's Operating Margin % is ranked higher than
78% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. SHPG: 8.61 )
Ranked among companies with meaningful Operating Margin % only.
SHPG' s Operating Margin % Range Over the Past 10 Years
Min: -56.61  Med: 22.5 Max: 35.13
Current: 8.61
-56.61
35.13
Net Margin % 4.90
SHPG's Net Margin % is ranked higher than
72% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. SHPG: 4.90 )
Ranked among companies with meaningful Net Margin % only.
SHPG' s Net Margin % Range Over the Past 10 Years
Min: -59.59  Med: 16.4 Max: 56.55
Current: 4.9
-59.59
56.55
ROE % 2.44
SHPG's ROE % is ranked higher than
77% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. SHPG: 2.44 )
Ranked among companies with meaningful ROE % only.
SHPG' s ROE % Range Over the Past 10 Years
Min: -90.17  Med: 17.69 Max: 49.41
Current: 2.44
-90.17
49.41
ROA % 1.07
SHPG's ROA % is ranked higher than
78% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. SHPG: 1.07 )
Ranked among companies with meaningful ROA % only.
SHPG' s ROA % Range Over the Past 10 Years
Min: -37.5  Med: 9.75 Max: 31.57
Current: 1.07
-37.5
31.57
ROC (Joel Greenblatt) % 13.17
SHPG's ROC (Joel Greenblatt) % is ranked higher than
80% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. SHPG: 13.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SHPG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -396.76  Med: 102.56 Max: 345.74
Current: 13.17
-396.76
345.74
3-Year Revenue Growth Rate 32.10
SHPG's 3-Year Revenue Growth Rate is ranked higher than
81% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SHPG: 32.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SHPG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.8  Med: 12.95 Max: 32.1
Current: 32.1
-0.8
32.1
3-Year EBITDA Growth Rate 5.60
SHPG's 3-Year EBITDA Growth Rate is ranked higher than
55% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SHPG: 5.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SHPG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.9  Med: 18.8 Max: 34.1
Current: 5.6
-1.9
34.1
3-Year EPS without NRI Growth Rate -25.60
SHPG's 3-Year EPS without NRI Growth Rate is ranked lower than
77% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. SHPG: -25.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SHPG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -25.6  Med: 30.4 Max: 68.8
Current: -25.6
-25.6
68.8
» SHPG's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SHPG Guru Trades in Q3 2016

Lee Ainslie 570,907 sh (+29634.74%)
Ken Fisher 166,168 sh (+276.87%)
Leon Cooperman 356,484 sh (+74.66%)
Steven Cohen 224,900 sh (+72.87%)
Third Avenue Management 68,224 sh (+42.61%)
John Paulson 60,000 sh (unchged)
Jeff Auxier 1,712 sh (unchged)
Kyle Bass 110,000 sh (unchged)
Tweedy Browne Global Value 6,803 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
Jeremy Grantham Sold Out
Paul Singer Sold Out
John Buckingham 19,504 sh (-0.36%)
Keeley Asset Management Corp 17,322 sh (-2.26%)
David Dreman 134 sh (-4.29%)
Daniel Loeb 900,000 sh (-5.26%)
First Eagle Investment 53,037 sh (-6.21%)
Murray Stahl 7,267 sh (-9.93%)
John Paulson 4,667,800 sh (-10.14%)
Tweedy Browne 36,304 sh (-14.07%)
Steve Mandel 1,694,675 sh (-32.99%)
Andreas Halvorsen 764,762 sh (-34.23%)
Mairs and Power 119,577 sh (-34.58%)
Julian Robertson 78,154 sh (-35.17%)
Pioneer Investments 15,699 sh (-56.24%)
Mario Gabelli 1,242 sh (-78.86%)
» More
Q4 2016

SHPG Guru Trades in Q4 2016

Scott Black 9,560 sh (New)
Lee Ainslie 1,425,420 sh (+149.68%)
Steven Cohen 410,700 sh (+82.61%)
Leon Cooperman 447,307 sh (+25.48%)
Julian Robertson 95,454 sh (+22.14%)
Andreas Halvorsen 919,604 sh (+20.25%)
Keeley Asset Management Corp 19,886 sh (+14.80%)
Steve Mandel 1,904,306 sh (+12.37%)
John Buckingham 20,722 sh (+6.24%)
John Paulson 160,000 sh (unchged)
Pioneer Investments 15,699 sh (unchged)
Tweedy Browne Global Value 6,803 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
Mario Gabelli Sold Out
David Dreman Sold Out
First Eagle Investment Sold Out
Daniel Loeb Sold Out
Jeff Auxier 1,705 sh (-0.41%)
Third Avenue Management 67,805 sh (-0.61%)
Tweedy Browne 35,534 sh (-2.12%)
Ken Fisher 151,274 sh (-8.96%)
John Paulson 4,206,100 sh (-9.89%)
Murray Stahl 6,000 sh (-17.43%)
Mairs and Power 24,659 sh (-79.38%)
» More
Q1 2017

SHPG Guru Trades in Q1 2017

Mario Gabelli 5,992 sh (New)
Larry Robbins 1,015,477 sh (New)
John Hussman 1,800 sh (New)
Jim Simons 319,177 sh (New)
Jana Partners 544,698 sh (New)
John Buckingham 27,469 sh (+32.56%)
Scott Black 12,080 sh (+26.36%)
Lee Ainslie 1,619,477 sh (+13.61%)
Leon Cooperman 487,307 sh (+8.94%)
Third Avenue Management 69,507 sh (+2.51%)
John Paulson 130,000 sh (unchged)
Murray Stahl 6,000 sh (unchged)
Jeff Auxier 1,705 sh (unchged)
Pioneer Investments 15,699 sh (unchged)
Tweedy Browne Global Value 6,803 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
Julian Robertson Sold Out
Tweedy Browne 34,653 sh (-2.48%)
Ken Fisher 144,475 sh (-4.49%)
John Paulson 3,998,100 sh (-4.95%)
Steve Mandel 1,714,306 sh (-9.98%)
Andreas Halvorsen 785,765 sh (-14.55%)
Mairs and Power 18,987 sh (-23.00%)
Steven Cohen 144,750 sh (-64.76%)
» More
Q2 2017

SHPG Guru Trades in Q2 2017

Pioneer Investments 67,699 sh (+331.23%)
Steven Cohen 267,300 sh (+84.66%)
Larry Robbins 1,722,977 sh (+69.67%)
Lee Ainslie 1,942,087 sh (+19.92%)
Mario Gabelli 6,904 sh (+15.22%)
Jim Simons 365,277 sh (+14.44%)
Scott Black 13,350 sh (+10.51%)
John Buckingham 29,879 sh (+8.77%)
Leon Cooperman 500,207 sh (+2.65%)
Andreas Halvorsen 797,053 sh (+1.44%)
Tweedy Browne Global Value 6,803 sh (unchged)
John Paulson 125,000 sh (unchged)
Jeff Auxier 1,705 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
John Hussman Sold Out
Jana Partners Sold Out
Steve Mandel Sold Out
Third Avenue Management 69,324 sh (-0.26%)
Tweedy Browne 32,874 sh (-5.13%)
John Paulson 3,481,600 sh (-12.92%)
Mairs and Power 15,981 sh (-15.83%)
Murray Stahl 5,000 sh (-16.67%)
Ken Fisher 55,800 sh (-61.38%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 Reduce -12.92%1.2%$162.35 - $190 $ 155.51-11%3,481,600
Leon Cooperman 2017-06-30 Add 2.65%0.09%$162.35 - $190 $ 155.51-11%500,207
Third Avenue Management 2017-06-30 Reduce -0.26%$162.35 - $190 $ 155.51-11%69,324
Ken Fisher 2017-06-30 Reduce -61.38%0.02%$162.35 - $190 $ 155.51-11%55,800
Tweedy Browne 2017-06-30 Reduce -5.13%0.01%$162.35 - $190 $ 155.51-11%32,874
Mario Gabelli 2017-06-30 Add 15.22%$162.35 - $190 $ 155.51-11%6,904
Steve Mandel 2017-06-30 Sold Out 1.57%$162.35 - $190 $ 155.51-11%0
John Paulson 2017-03-31 Reduce -4.95%0.45%$161.71 - $186.3 $ 155.51-11%3,998,100
Steve Mandel 2017-03-31 Reduce -9.98%0.17%$161.71 - $186.3 $ 155.51-11%1,714,306
Leon Cooperman 2017-03-31 Add 8.94%0.28%$161.71 - $186.3 $ 155.51-11%487,307
Ken Fisher 2017-03-31 Reduce -4.49%$161.71 - $186.3 $ 155.51-11%144,475
Third Avenue Management 2017-03-31 Add 2.51%0.01%$161.71 - $186.3 $ 155.51-11%69,507
Tweedy Browne 2017-03-31 Reduce -2.48%$161.71 - $186.3 $ 155.51-11%34,653
Mario Gabelli 2017-03-31 New Buy0.01%$161.71 - $186.3 $ 155.51-11%5,992
Julian Robertson 2017-03-31 Sold Out 2.95%$161.71 - $186.3 $ 155.51-11%0
John Paulson 2016-12-31 Reduce -9.89%0.98%$163.77 - $197.7 $ 155.51-12%4,206,100
Steve Mandel 2016-12-31 Add 12.37%0.19%$163.77 - $197.7 $ 155.51-12%1,904,306
Leon Cooperman 2016-12-31 Add 25.48%0.68%$163.77 - $197.7 $ 155.51-12%447,307
Ken Fisher 2016-12-31 Reduce -8.96%0.01%$163.77 - $197.7 $ 155.51-12%151,274
Julian Robertson 2016-12-31 Add 22.14%0.53%$163.77 - $197.7 $ 155.51-12%95,454
Third Avenue Management 2016-12-31 Reduce -0.61%$163.77 - $197.7 $ 155.51-12%67,805
Tweedy Browne 2016-12-31 Reduce -2.12%$163.77 - $197.7 $ 155.51-12%35,534
Keeley Asset Management Corp 2016-12-31 Add 14.80%0.02%$163.77 - $197.7 $ 155.51-12%19,886
David Dreman 2016-12-31 Sold Out 0.02%$163.77 - $197.7 $ 155.51-12%0
Mario Gabelli 2016-12-31 Sold Out $163.77 - $197.7 $ 155.51-12%0
First Eagle Investment 2016-12-31 Sold Out 0.03%$163.77 - $197.7 $ 155.51-12%0
Martin Whitman 2016-10-31 Add 46.28%0.3%$168.64 - $206.56 $ 155.51-20%61,638
John Paulson 2016-09-30 Reduce -10.14%1.01%$185.2 - $206.56 $ 155.51-20%4,667,800
Steve Mandel 2016-09-30 Reduce -32.99%0.71%$185.2 - $206.56 $ 155.51-20%1,694,675
Leon Cooperman 2016-09-30 Add 74.66%0.91%$185.2 - $206.56 $ 155.51-20%356,484
Ken Fisher 2016-09-30 Add 276.87%0.04%$185.2 - $206.56 $ 155.51-20%166,168
Julian Robertson 2016-09-30 Reduce -35.17%2.52%$185.2 - $206.56 $ 155.51-20%78,154
Third Avenue Management 2016-09-30 Add 42.61%0.18%$185.2 - $206.56 $ 155.51-20%68,224
First Eagle Investment 2016-09-30 Reduce -6.21%$185.2 - $206.56 $ 155.51-20%53,037
Tweedy Browne 2016-09-30 Reduce -14.07%0.03%$185.2 - $206.56 $ 155.51-20%36,304
Keeley Asset Management Corp 2016-09-30 Reduce -2.26%$185.2 - $206.56 $ 155.51-20%17,322
Mario Gabelli 2016-09-30 Reduce -78.86%0.01%$185.2 - $206.56 $ 155.51-20%1,242
David Dreman 2016-09-30 Reduce -4.29%$185.2 - $206.56 $ 155.51-20%134
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:JAZZ, NAS:ALKS, NAS:PRTA, NAS:AMRN, NAS:AVDL, NAS:NBRV, NAS:NVET » details
Traded in other countries:SHPG.Austria, S7E.Germany, SHPG N.Mexico, SHP.UK, SHPGF.USA,
Headquarter Location:Ireland
Shire PLC is a biotechnology company focused mainly in the research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005 that established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007 that brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Guru Investment Theses on Shire PLC

Keeley All Cap Value Fund Comments on Shire - Jan 27, 2017

Given the volatile Health Care sector this quarter, the Fund’s position in Shire (NASDAQ:SHPG) was also a leading detractor. Headline risk regarding potential pharmaceutical price controls has impacted the stock. With continued synergies from its acquisition of Baxalta and trading at 11x earnings, we feel the stock remains quite attractive.



From the Keeley All Cap Value Fund fourth quarter 2016 commentary.







Check out Keeley Asset Management Corp latest stock trades

Top Ranked Articles about Shire PLC

Stocks That Fell to 3-Year Lows in the Week of August 25 Shire PLC (SHPG), Coty Inc (COTY), Viacom Inc (VIAB), and L Brands Inc (LB) have declined to their respective three-year lows.
Shire PLC (NASDAQ:SHPG), Coty Inc (NYSE:COTY), Viacom Inc (NASDAQ:VIAB), and L Brands Inc (NYSE:LB) have declined to their three-year lows. Read more...
Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease
Shire plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older
The Fading Fortunes of John Paulson Hedge fund guru won attention for his strategy during the subprime crisis, but lately he’s been getting attention for the wrong reasons
John Paulson (Trades, Portfolio) was once a darling of Wall Street, having handsomely profited because of his smart bets on the subprime crisis while many of his counterparts suffered. Read more...
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Shire plc (SHPG)
Shire to Participate at the Jefferies Healthcare Conference
Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference
Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI)

Ratios

vs
industry
vs
history
PE Ratio 55.75
SHPG's PE Ratio is ranked lower than
88% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. SHPG: 55.75 )
Ranked among companies with meaningful PE Ratio only.
SHPG' s PE Ratio Range Over the Past 10 Years
Min: 12.4  Med: 27.93 Max: 161.29
Current: 55.75
12.4
161.29
Forward PE Ratio 9.54
SHPG's Forward PE Ratio is ranked higher than
84% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. SHPG: 9.54 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 56.56
SHPG's PE Ratio without NRI is ranked lower than
80% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. SHPG: 56.56 )
Ranked among companies with meaningful PE Ratio without NRI only.
SHPG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.87  Med: 23.64 Max: 106.93
Current: 56.56
12.87
106.93
Price-to-Owner-Earnings 64.29
SHPG's Price-to-Owner-Earnings is ranked lower than
96% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. SHPG: 64.29 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SHPG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.33  Med: 24.94 Max: 763.03
Current: 64.29
11.33
763.03
PB Ratio 1.45
SHPG's PB Ratio is ranked higher than
82% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. SHPG: 1.45 )
Ranked among companies with meaningful PB Ratio only.
SHPG' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 5.49 Max: 14.19
Current: 1.45
1.39
14.19
PS Ratio 3.06
SHPG's PS Ratio is ranked higher than
77% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. SHPG: 3.06 )
Ranked among companies with meaningful PS Ratio only.
SHPG' s PS Ratio Range Over the Past 10 Years
Min: 2.25  Med: 4.56 Max: 9.27
Current: 3.06
2.25
9.27
Price-to-Free-Cash-Flow 28.11
SHPG's Price-to-Free-Cash-Flow is ranked lower than
98% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. SHPG: 28.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SHPG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.98  Med: 27.13 Max: 107.23
Current: 28.11
10.98
107.23
Price-to-Operating-Cash-Flow 13.28
SHPG's Price-to-Operating-Cash-Flow is ranked higher than
65% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. SHPG: 13.28 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SHPG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.66  Med: 17.45 Max: 27
Current: 13.28
7.66
27
EV-to-EBIT 51.99
SHPG's EV-to-EBIT is ranked lower than
88% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. SHPG: 51.99 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 17.8 Max: 173.7
Current: 51.99
-10.7
173.7
EV-to-EBITDA 15.29
SHPG's EV-to-EBITDA is ranked lower than
51% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. SHPG: 15.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.8  Med: 14.2 Max: 34.2
Current: 15.29
-11.8
34.2
EV-to-Revenue 4.48
SHPG's EV-to-Revenue is ranked higher than
70% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. SHPG: 4.48 )
Ranked among companies with meaningful EV-to-Revenue only.
SHPG' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.6  Med: 4.8 Max: 10
Current: 4.48
2.6
10
PEG Ratio 4.65
SHPG's PEG Ratio is ranked lower than
78% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. SHPG: 4.65 )
Ranked among companies with meaningful PEG Ratio only.
SHPG' s PEG Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.16 Max: 4.9
Current: 4.65
0.47
4.9
Shiller PE Ratio 35.37
SHPG's Shiller PE Ratio is ranked lower than
54% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. SHPG: 35.37 )
Ranked among companies with meaningful Shiller PE Ratio only.
SHPG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 34.4  Med: 98.3 Max: 469
Current: 35.37
34.4
469
Current Ratio 0.96
SHPG's Current Ratio is ranked lower than
88% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. SHPG: 0.96 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.69 Max: 7.43
Current: 0.96
0.52
7.43
Quick Ratio 0.52
SHPG's Quick Ratio is ranked lower than
92% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. SHPG: 0.52 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.47 Max: 7.07
Current: 0.52
0.4
7.07
Days Inventory 283.37
SHPG's Days Inventory is ranked lower than
83% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. SHPG: 283.37 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 189.11 Max: 283.37
Current: 283.37
126.5
283.37
Days Sales Outstanding 68.33
SHPG's Days Sales Outstanding is ranked lower than
55% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. SHPG: 68.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 69.72 Max: 83.8
Current: 68.33
47.71
83.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.59
SHPG's Dividend Yield % is ranked lower than
79% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. SHPG: 0.59 )
Ranked among companies with meaningful Dividend Yield % only.
SHPG' s Dividend Yield % Range Over the Past 10 Years
Min: 0.23  Med: 0.41 Max: 0.7
Current: 0.59
0.23
0.7
Dividend Payout Ratio 0.47
SHPG's Dividend Payout Ratio is ranked higher than
94% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. SHPG: 0.47 )
Ranked among companies with meaningful Dividend Payout Ratio only.
SHPG' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.47
Current: 0.47
0.04
0.47
3-Year Dividend Growth Rate 26.40
SHPG's 3-Year Dividend Growth Rate is ranked higher than
80% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. SHPG: 26.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
SHPG' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.7 Max: 57.8
Current: 26.4
0
57.8
Forward Dividend Yield % 0.59
SHPG's Forward Dividend Yield % is ranked lower than
62% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.26 vs. SHPG: 0.59 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.52
SHPG's 5-Year Yield-on-Cost % is ranked lower than
52% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. SHPG: 1.52 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
SHPG' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.6  Med: 1.07 Max: 1.83
Current: 1.52
0.6
1.83
3-Year Average Share Buyback Ratio -14.80
SHPG's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. SHPG: -14.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -50.3  Med: -2.15 Max: 0.4
Current: -14.8
-50.3
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.32
SHPG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
77% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. SHPG: 1.32 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SHPG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.13  Med: 1.79 Max: 3.78
Current: 1.32
1.13
3.78
Price-to-Median-PS-Value 0.67
SHPG's Price-to-Median-PS-Value is ranked higher than
65% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. SHPG: 0.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SHPG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.53  Med: 0.96 Max: 2.75
Current: 0.67
0.53
2.75
Price-to-Peter-Lynch-Fair-Value 3.08
SHPG's Price-to-Peter-Lynch-Fair-Value is ranked lower than
80% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. SHPG: 3.08 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
SHPG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.39 Max: 4.54
Current: 3.08
0.54
4.54
Earnings Yield (Greenblatt) % 1.92
SHPG's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. SHPG: 1.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SHPG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13.1  Med: 5.1 Max: 8.4
Current: 1.92
-13.1
8.4
Forward Rate of Return (Yacktman) % 19.98
SHPG's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. SHPG: 19.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SHPG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.5  Med: 2.5 Max: 29
Current: 19.98
1.5
29

More Statistics

Revenue (TTM) (Mil) $14,576.30
EPS (TTM) $ 2.52
Beta1.73
Short Percentage of Float0.00%
52-Week Range $139.36 - 209.22
Shares Outstanding (Mil)302.70 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 15,053 15,694 16,685 17,321
EPS ($) 14.91 16.39 18.82 19.22
EPS without NRI ($) 14.91 16.39 18.82 19.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.77%
Dividends per Share ($) 0.97 1.10 1.38
» More Articles for SHPG

Headlines

Articles On GuruFocus.com
5 Health Care Companies Gurus Are Buying Sep 05 2017 
Stocks That Fell to 3-Year Lows in the Week of August 25 Aug 27 2017 
Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Autho Jun 22 2017 
Shire plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts of a Single-Entity Amphetamine Product) - A Ne Jun 20 2017 
Where to Find Value in a Lofty Market Jun 16 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Shire plc (SHPG) Jun 08 2017 
The Fading Fortunes of John Paulson Jun 08 2017 
Shire to Participate at the Jefferies Healthcare Conference May 25 2017 
Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psyc May 16 2017 
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalm May 01 2017 

More From Other Websites
Neos Therapeutics ADHD Drug Adzenys Receives Approval in US Sep 18 2017
What’s Cooperman’s View on Shire? Sep 15 2017
Top Research Reports for Disney, Kraft Heinz & CVS Health Sep 12 2017
Alnylam Shares Plunge on Patient Death, Dosing Suspended Sep 08 2017
Here's Why Shire PLC Stock Fell 10% in August Sep 07 2017
Shire plc : Total voting rights Sep 01 2017
Corporate News Blog - Sanofi Completes Acquisition of Vaccines Biotechnology Company, Protein... Aug 30 2017
Roche (RHHBY) Hemophilia A Drug Granted Priority Review Aug 24 2017
Shire plc : Director/PDMR Shareholding Aug 23 2017
Shire chief financial officer joins Boston ag-tech startup Aug 23 2017
UPDATE: Shire: There Goes the CFO! Aug 21 2017
Shire plc Director and Senior Management Changes Aug 21 2017
Shire Files Marketing Application for Lifitegrast in Europe Aug 16 2017
Shire applies for European approval of potential blockbuster eye drop Aug 15 2017
Shire Gains as it Seeks European Approval For Dry Eye Treatment Aug 15 2017
Shire announces submission of lifitegrast Marketing Authorization Application for treatment of dry... Aug 15 2017
Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View Aug 04 2017
Shire plc : Half-yearly report Aug 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}